Danaher Corporation (NYSE:DHR) – Analysts at Jefferies Group increased their Q3 2017 earnings per share estimates for Danaher Corporation in a research note issued to investors on Thursday. Jefferies Group analyst B. Couillard now anticipates that the conglomerate will post earnings of $0.95 per share for the quarter, up from their previous estimate of $0.93. Jefferies Group also issued estimates for Danaher Corporation’s Q4 2017 earnings at $1.16 EPS, FY2017 earnings at $3.95 EPS, Q1 2018 earnings at $1.01 EPS, Q2 2018 earnings at $1.08 EPS, Q3 2018 earnings at $1.06 EPS, Q4 2018 earnings at $1.18 EPS and FY2019 earnings at $4.70 EPS.
DHR has been the subject of a number of other research reports. Wells Fargo & Company reaffirmed a “market perform” rating on shares of Danaher Corporation in a research note on Saturday. Credit Suisse Group reaffirmed a “buy” rating and issued a $93.00 price objective on shares of Danaher Corporation in a research note on Wednesday, May 24th. Janney Montgomery Scott lowered shares of Danaher Corporation from a “buy” rating to a “neutral” rating in a research note on Wednesday, June 7th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $97.00 price objective on shares of Danaher Corporation in a research note on Wednesday, June 21st. Finally, Vetr raised shares of Danaher Corporation from a “buy” rating to a “strong-buy” rating and set a $94.18 price objective for the company in a research note on Thursday, April 20th. One analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $91.98.
TRADEMARK VIOLATION NOTICE: This story was first posted by BNB Daily and is the property of of BNB Daily. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/q3-2017-eps-estimates-for-danaher-corporation-dhr-boosted-by-analyst-updated-updated-updated.html.
Danaher Corporation (DHR) opened at 83.05 on Monday. Danaher Corporation has a 52 week low of $75.71 and a 52 week high of $88.01. The stock has a market cap of $57.69 billion, a price-to-earnings ratio of 26.51 and a beta of 1.05. The firm’s 50 day moving average price is $84.75 and its 200-day moving average price is $84.18.
Danaher Corporation (NYSE:DHR) last issued its quarterly earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.02. Danaher Corporation had a return on equity of 11.15% and a net margin of 12.63%. The company had revenue of $4.51 billion for the quarter, compared to analyst estimates of $4.50 billion. During the same quarter in the prior year, the company posted $0.90 EPS. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 30th will be paid a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.67%. The ex-dividend date is Wednesday, June 28th. Danaher Corporation’s payout ratio is presently 17.83%.
In related news, EVP William K. Daniel sold 17,444 shares of Danaher Corporation stock in a transaction on Tuesday, April 25th. The shares were sold at an average price of $83.07, for a total value of $1,449,073.08. Following the transaction, the executive vice president now owns 132,995 shares in the company, valued at approximately $11,047,894.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Angela S. Lalor sold 10,815 shares of Danaher Corporation stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $84.16, for a total transaction of $910,190.40. Following the completion of the transaction, the senior vice president now owns 39,020 shares in the company, valued at approximately $3,283,923.20. The disclosure for this sale can be found here. 12.20% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Danaher Corporation by 2,530.9% in the first quarter. BlackRock Inc. now owns 37,967,922 shares of the conglomerate’s stock valued at $3,247,398,000 after buying an additional 36,524,795 shares during the period. Vanguard Group Inc. increased its position in shares of Danaher Corporation by 3.9% in the first quarter. Vanguard Group Inc. now owns 40,967,631 shares of the conglomerate’s stock valued at $3,503,962,000 after buying an additional 1,530,015 shares during the period. MARSHALL WACE ASIA Ltd purchased a new position in shares of Danaher Corporation during the first quarter valued at approximately $116,462,000. Marshall Wace North America L.P. purchased a new position in shares of Danaher Corporation during the first quarter valued at approximately $116,462,000. Finally, Parnassus Investments CA increased its position in shares of Danaher Corporation by 15.3% in the first quarter. Parnassus Investments CA now owns 8,622,528 shares of the conglomerate’s stock valued at $712,738,000 after buying an additional 1,143,284 shares during the period. Hedge funds and other institutional investors own 76.34% of the company’s stock.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.